河北医学2024，Vol.30Issue(9)：1483-1488,6.DOI:10.3969/j.issn.1006-6233.2024.09.013
中性粒细胞/淋巴细胞CD4+/CD8+与PD-1抑制剂免疫治疗肺癌疗效及OS的关系研究
Study on the Relationship between Neutrophils/Lymphocytes CD4+/CD8+and the Efficacy and OS of PD-1 Inhibitor Immunotherapy for Lung Cancer
摘要
Abstract
Objective:To observe the changes in neutrophil/lymphocyte ratio(NLR)and CD4+/CD8+in patients with lung cancer after treatment with programmed death receptor-1(PD-1)inhibitor,and to ana-lyze the correlation between changes of two indicators and efficacy and overall survival time(OS).Methods:A total of 94 patients with pulmonary cancer were included in the hospital from December 2019 to March 2022.The changes of NLR and CD4+/CD8+were observed among patients with different efficacies after PD-1 treatment,and the association with different efficacies after immunotherapy and OS after 2 years of follow-up was analyzed.Results:There were statistically significant differences in NLR and CD4+/CD8+among patients with different efficacies after PD-1 inhibitor treatment(P<0.05).The NLR and CD4+/CD8+in the CR group and PR group were statistically different from those in the SD group and CD group(P<0.05),and there was a statistical significance in NLR between the SD group and PD group(P<0.05).Univariate analysis showed that the pathological type,TNM staging,differentiation degree,age,NLR and CD4+/CD8+were statistically significant between the effective group and the ineffective group after immunotherapy(P<0.05).Logistic re-gression model found that small cell type,TNM staging(stage Ⅳ),differentiation degree(low differentia-tion),older age,and high NLR were risk factors for poor efficacy of immunotherapy(P<0.05),while high CD4+/CD8+was a protective factor for poor efficacy of immunotherapy(P<0.05).ROC curve showed that the areas under the curves(AUCs)of NLR and CD4+/CD8+in evaluating the efficacy were 0.785 and 0.777 re-spectively,and the AUC of NLR combined with CD4+/CD8+was 0.871,which was significantly higher than that of single index(P<0.05).Spearman correlation analysis suggested that NLR was negatively correlated with OS(r=-0.341,P<0.05),and CD4+/CD8+was positively correlated with OS(r=0.323,P<0.05).Conclusion:The NLR is lower while the CD4+/CD8+is higher among patients with pulmonary cancer who are with effective PD-1 inhibitor treatment,and the two indexes have certain evaluated values on the efficacy of immunotherapy and also have a certain association with OS.关键词
肺癌/T淋巴细胞/中性粒细胞与淋巴细胞比值/程序性死亡受体-1Key words
Lung cancer/T lymphocytes/Neutrophil-to-lymphocyte ratio/Programmed death receptor-1引用本文复制引用
吕志芳,王明,程飞飞,王玲,钱建伟..中性粒细胞/淋巴细胞CD4+/CD8+与PD-1抑制剂免疫治疗肺癌疗效及OS的关系研究[J].河北医学,2024,30(9):1483-1488,6.基金项目
2022年度安徽省卫生健康科研项目,(编号:AHWJ20226099) （编号:AHWJ20226099）
